These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]. Tachibana E; Watanabe I; Nagao K; Kanmatsuse K J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271 [TBL] [Abstract][Full Text] [Related]
4. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Rosenson RS Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930 [TBL] [Abstract][Full Text] [Related]
10. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). Yokoyama M; Origasa H; Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313 [TBL] [Abstract][Full Text] [Related]
11. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Guijarro C; Keane WF Miner Electrolyte Metab; 1996; 22(1-3):147-52. PubMed ID: 8676808 [TBL] [Abstract][Full Text] [Related]
12. [Inhibitors of HMG CoA reductase: new modes of action, new indications?]. Essig M; Vrtovsnik F; Friedlander G Therapie; 2000; 55(1):43-9. PubMed ID: 10860000 [TBL] [Abstract][Full Text] [Related]
15. [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)]. Igel M; Sudhop T; von Bergmann K Arzneimittelforschung; 2003; 53(8):545-53. PubMed ID: 13677244 [TBL] [Abstract][Full Text] [Related]
16. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes]. Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071 [TBL] [Abstract][Full Text] [Related]
17. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080 [TBL] [Abstract][Full Text] [Related]
18. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments. MacNeil P Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928 [TBL] [Abstract][Full Text] [Related]
19. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Mason RP; Walter MF; Day CA; Jacob RF Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019 [TBL] [Abstract][Full Text] [Related]
20. A review of clinical trials comparing HMG-CoA reductase inhibitors. Illingworth DR; Tobert JA Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]